TERT promoter mutations occur in melanoma as frequently as [4], or more frequently [5] than BRAF mutations, and yet mainly BRAF mutant specific cfDNA is being used to monitor melanoma patients for response to therapy and disease progression [26]. This evidence concerns the gene BRAF and melanoma.